SIGNATURE WORK
CONFERENCE & EXHIBITION 2024

This paper explores the relationship between the revenue of pharmaceutical companies and ESG score with its factors. Despite the growing emphasis on ESG as a catalyst for achieving immediate growth, evidence from the pharmaceutical sector suggests a more nuanced impact on revenue. This study explores the underlying reasons why ESG initiatives may not directly contribute to immediate financial gains in this industry and provides corresponding policy recommendations.